Searched for
BIOCON BIOLOGICS UPDATES
'Thank God' Kiran Mazumdar Shaw did not become a doctor: When Dr Devi Shetty shared a life lesson from Biocon founder's inspiring journeyA missed medical college admission propelled Kiran Mazumdar-Shaw towards a different path, ultimately leading to the founding of Biocon. Re...- Biocon shares rally nearly 6% after unit receives USFDA nod for cancer drugBiocon's shares surged following USFDA approval for Jobevne, a biosimilar to Avastin, used in treating various cancers. This marks Biocon's...
- Biocon shares in focus after Q3 PAT drops 96% YoY, 1.5% additional stake acquisition in subsidiaryBiocon share price: Biocon reported a 96% year-on-year (YoY) decline in net profit, which fell to Rs 25 crore in Q3FY25. In comparison, the...
- Stocks in news: HCL Tech, Angel One, Dmart, Just Dial, Signature GlobalShares of HCL Tech, Angel One and Delta Corp will be in focus as the companies will announce their third quarter results later today.
- Biocon shares surge over 4% after Malaysia unit gets clearance from the USFDABiocon shares increased by 4.5% after the US FDA classified its Malaysian insulin facilities as Voluntary Action Indicated. This followed a...
- Biocon shares zoom 4% as Jefferies upgrades to "hold" amid positive news inflow, sets Rs 400 targetBiocon share price: This upgrade reflects a more positive outlook on the company following recent favorable news flow, particularly concern...
- Stocks to buy today: CLSA upgrades ONGC; Citi initiates buy on Hyundai Motor IndiaCLSA has upgraded ONGC to "High Conviction Overweight-PF," citing multiple production and realization triggers, alongside attractive valuat...
- Biocon shares surge 5% after USFDA classifies Bengaluru site as VAIBiocon Share Price: Biocon shares surged 5.4% after FDA classified its Bengaluru facility as Voluntary Action Indicated (VAI). The stock is...
- Dr Reddy's Laboratories jumps into the fray for Biogen's biosimilarsDr Reddy's Laboratories (DRL) and Intas Pharmaceuticals, both Indian companies, are reportedly in the race to acquire the biosimilar produc...
- Competition Commission of India clears Kotak-Biocon Biologics dealThe investment will help Biocon Biologics' acquisition of the biosimilars business of its partner Viatris.
- Biocon Biologics announces top leadership appointmentsBiocon Biologics Ltd has made several key leadership appointments, including appointing Rhonda Duffy as Chief Operating Officer and Sandeep...
- Q4 results today: What's in store for Ashok Leyland, NMDC and BioconAshok Leyland's Q4 net sales are expected to increase by 35% YoY to Rs 11,786 crore, with net profit likely to decline 10% to Rs 807 crore....
- Biocon plunges 5% even as Q1 profit rises 71%Siddharth Mittal, CEO & Managing Director, Biocon, said, “The strong year-on-year growth of the segment was driven by both our API and Form...
- Market movers: LIC shareholders lose Rs 77K crore in four days; Paytm gets 4% lift ahead of Q4 showLIC stock has fallen 13 per cent from its issue price of Rs 949 to Rs 826. In that process, shareholders of the company have lost over Rs 7...
- Biocon reports 64% jump in Q4 net riding on biologicsBiocon reported a 64 per cent jump in its net profit for the quarter ending March 2019.
- Biocon-Mylan's cancer drug gets USFDA nodFulphila is expected to contribute to Biocon’s revenue in FY19, as well as to its profits through a profitshare arrangement with Mylan.
- Biocon rallies over 7% as USFDA issues CRL for proposed biosimilarThis product is a part of the biosimilars portfolio being developed jointly by Biocon and Mylan, the company said in a BSE filing.
- USFDA issues CRL for proposed biosimilar Pegfilgrastim: BioconThe company said it does not expect the CRL to impact the timing of the launch of biosimilar Pegfilgrastim in the US market.
- Biocon gets CRL from USFDA for anti-cancer drugThe company, however, said it does not expect this CRL to impact the commercial launch timing of biosimilar Pegfilgrastim in the US.
- Biocon targets emerging, developed markets with biosimilars"Biocon aims to provide high quality biosimilars to patients across the world, both in emerging and developed markets," Kiran Mazumdar-Shaw...
Load More
